Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases

BACKGROUND: The liver is the most common site of metastasis in colorectal cancer. In patients with unresectable colorectal liver metastases, the 5-year survival rate is less than 5%. Many patients with colorectal liver metastases require effective subsequent therapy after the failure of standard fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Haohao, Zheng, Chuansheng, Fan, Li, Xiong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219774/
https://www.ncbi.nlm.nih.gov/pubmed/37251557
http://dx.doi.org/10.1155/2022/5366011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219774/
https://www.ncbi.nlm.nih.gov/pubmed/37251557
http://dx.doi.org/10.1155/2022/5366011

Ejemplares similares